KRYS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Krystal Biotech Inc (KRYS) is not an immediate buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. While the company has strong growth potential and positive analyst sentiment, the technical indicators suggest a neutral to slightly bearish short-term trend, and insider selling raises concerns. Waiting for a more favorable entry point or additional positive catalysts would be prudent.
The MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 37.842, and moving averages are converging, showing no clear trend. The stock is trading below the pivot level of 265.739, with support at 256.409 and resistance at 275.068.
Strong Q4 financial performance with revenue up 17.52% YoY and net income up 13.02% YoY.
Positive analyst sentiment with multiple price target increases and buy ratings.
Promising pipeline developments, including Vyjuvek growth and upcoming pivotal trials.
Insider selling by Daniel S. Janney, reducing his stake significantly, which may indicate reduced confidence.
Technical indicators show bearish momentum.
Gross margin slightly declined YoY, which could signal cost pressures.
In Q4 2025, revenue increased by 17.52% YoY to $107.1M, net income rose by 13.02% YoY to $51.4M, and EPS grew by 11.84% YoY to 1.7. However, gross margin dropped slightly by 0.76% YoY to 93.85%.
Analysts are overwhelmingly positive on KRYS, with multiple price target increases in February 2026. Targets range from $284 to $371, reflecting confidence in Vyjuvek's growth and the company's pipeline. All analysts maintain a Buy rating.
